A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis

Table 2 Median time to response

Response	Median time to response, days (95 % CI)			p value
Response	ETN 50 mg–ETN 25 mg (n = 21)	ETN 25 mg–ACT 10 mg (n = 19)	ACT 10 mg (n = 18)	p value
PASI 75	126 (56, 146)	146 (124, NA)	NA (127, NA)	0.0448
PASI 50	56 (28, 56)	56 (54, 84)	126 (56, NA)	0.0033
PGA clear/almost-clear	167 (55, 172)	165 (59, NA)	NA (87, NA)	0.3536

Abbreviations: ACT acitretin, CI confidence interval, ETN etanercept, NA not available, PASI Psoriasis Area Severity Index, PGA Physician’s Global Assessment

ISSN: 1471-5945